Exploration of the role of neural-type receptors and the ECM proteins SPARC and Tenascin C in the bone marrow HSC-niche unit
Exploration of the role of neural-type receptors and the ECM proteins SPARC and Tenascin C in the bone marrow HSC-niche unit
批准号:
246083836
负责人:
Professor Dr. Daniel Nowak
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Units
财政年份:
2013
资助国家:
德国
项目状态:
已结题
起止时间:
2012-12-31 至 2019-12-31
中文摘要
骨髓增生异常综合征(MDS)是一种以造血功能低下、外周血细胞减少和骨髓细胞增生异常为特征的克隆性血液学疾病,发展为急性髓性白血病(AML)的风险增加。MDS不仅是一种造血细胞间室的疾病,而且骨髓生态位的改变影响骨髓肿瘤的发展。基于这一假设,在之前的联合合作工作中,我们已经建立了一个基于患者来源的CD34+造血干细胞(hsc)和骨髓来源的基质细胞(MSCs)共同移植的强大的人类MDS异种移植模型。我们的研究揭示了MDS造血干细胞诱导的微环境重塑,以优先支持其自身的生长。MDS来源的MSCs中显著过表达的关键因子之一是细胞外基质蛋白分泌的酸性和富含半胱氨酸的蛋白(SPARC)。在多种实体瘤中,SPARC被认为是介导肿瘤细胞与周围基质相互作用和转移的中心因子。在血液恶性肿瘤中,我们可以证明骨髓间质室中SPARC的缺失可以保护造血细胞免受化疗毒性的影响。在目前的建议中,我们的目标是使用我们独特的MDS异种移植模型来阐明SPARC的分子机制,以便可能确定针对髓系肿瘤异常间质室的新治疗策略。为了实现这一点,我们将以前的小鼠SPARC敲除菌株与NSG模型杂交,以产生NSG SPARC敲除小鼠。原代MDS衍生和健康骨髓样本将被异种移植到该模型中,以研究骨髓生态位中SPARC缺失或存在的生物学效应。除了移植率外,MDS异种移植物的克隆骨髓组成将通过对原发患者样本和MDS异种移植物的定量突变和免疫表型分析进行分析。为了分析造血间室和骨髓间质之间具有指导意义的串扰,我们将在暴露于MDS造血干细胞后对原代分选的基质细胞组分进行全转录组RNA测序,包括内皮细胞、成骨细胞和间充质干细胞等亚组分。除此之外,我们将使用我们的模型作为临床前平台来测试是否通过添加外源性SPARC或其抑制来操纵骨髓生态位,可以实现对MDS生物学,克隆组成或功能性血液成分的改善的积极影响。在其他肿瘤实体(如硼替佐米和nab-紫杉醇)的背景下,涉及SPARC生物学的药理学物质的应用将被评估为针对MDS骨髓基质的潜在治疗方法。
英文摘要
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis, peripheral cytopenias and dysplastic bone marrow cells, with increased risk of evolution to acute myeloid leukemia (AML). MDS is not only a disease of the hematopoietic cell compartment but also alterations in the bone marrow niche influence the development of myeloid neoplasms. Based on this hypothesis, in previous joint collaborative work we have established a robust xenograft model of human MDS based on the co-transplantation of patient derived CD34+ hematopoietic stem cells (HSCs) and bone marrow (BM) derived stromal cells (MSCs). Our work revealed an instructive remodeling of the microenvironment induced by MDS HSCs to preferentially support their own growth. One of the key factors significantly overexpressed in MDS derived MSCs was the extracellular matrix protein secreted protein acidic and rich in cysteine (SPARC). SPARC has been implicated as a central factor in mediating tumor cell interaction with surrounding stroma and metastasis of a variety of solid tumors. In hematologic malignancies, we could show that loss of SPARC in the bone marrow stroma compartment protects hematopoietic cells from chemotherapy toxicity. In the current proposal we aim to use our unique MDS xenograft model to elucidate the molecular mechanisms of SPARC in order to possibly identify new therapeutic strategies that are targeted against the aberrant stroma compartment in myeloid neoplasms. To accomplish this we have crossed previous murine SPARC knockout strains with the NSG model in order to generate NSG SPARC knockout mice. Primary MDS derived and healthy bone marrow samples will be xenotransplanted into this model to study the biologic effect of absence or presence SPARC in the bone marrow niche. As a readout beside engraftment rates, the clonal bone marrow composition of the MDS xenografts will be analyzed via quantitative mutation and immunophenotypic analyses of primary patient samples and MDS xenografts. To analyze the instructive crosstalk between the hematopoietic compartment and the bone marrow stroma, we will perform whole transcriptome RNA sequencing in primary sorted stroma cell fractions, including subfractions such as endothelial cells, osteoblasts and mesenchymal stem cells after exposure to the MDS HSCs in vivo. Beyond this, we will use our model as a pre-clinical platform to test whether by manipulation of the bone marrow niche with either addition of exogenous SPARC or its inhibition, positive effects on MDS biology, clonal composition or improvement of functional blood components can be achieved. The application of pharmacologic substances that have been implicated in the biology of SPARC in the context of other tumor entities such as Bortezomib and nab-Paclitaxel will be evaluated as potential therapies targeting the bone marrow stroma of MDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifikation von Schlüsselgenen in der Pathogenese Myelodysplastischer Syndrome (MDS) mittels "high-density" Genomanalyse
-
批准号:50848630
-
项目类别:Research Fellowships
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Professor Dr. Daniel Nowak
-
依托单位:
国内基金
海外基金
水稻根长与抗旱基因RoLe1的克隆与分子机制解析
-
批准号:32401809
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:李颖秀
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
Sestrin2抑制内质网应激对早产儿视网膜病变的调控作用及其机制研究
-
批准号:82371070
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵培泉
-
依托单位: